-
Players pay tribute to Bondi victims at Ashes Test
-
Costa Rican president survives second Congress immunity vote
-
Married couple lauded for effort to thwart Bondi Beach shootings
-
Australia holds first funerals for Bondi Beach attack victims
-
Trump has 'alcoholic's personality,' chief of staff says in bombshell interview
-
Rob Reiner killing: son to be charged with double murder
-
Chelsea battle into League Cup semis to ease pressure on Maresca
-
Netflix boss promises Warner Bros films would still be seen in cinemas
-
Grok spews misinformation about deadly Australia shooting
-
Stocks mostly retreat on US jobs, oil drops on Ukraine hopes
-
Artificial snow woes for Milan-Cortina Winter Olympics organisers
-
Trump imposes full travel bans on seven more countries, Palestinians
-
New Chile leader calls for end to Maduro 'dictatorship'
-
Shiffrin extends slalom domination with Courchevel win
-
Doctor sentenced for supplying ketamine to 'Friends' star Perry
-
Tepid 2026 outlook dents Pfizer shares
-
Rob Reiner murder: son not medically cleared for court
-
FIFA announces $60 World Cup tickets for 'loyal fans'
-
Dembele and Bonmati scoop FIFA Best awards
-
Shiffrin dominates first run in Courchevel slalom
-
EU weakens 2035 combustion-engine ban to boost car industry
-
Arctic sees unprecedented heat as climate impacts cascade
-
French lawmakers adopt social security budget, suspend pension reform
-
Afrikaners mark pilgrimage day, resonating with their US backers
-
Lawmakers grill Trump officials on US alleged drug boat strikes
-
Hamraoui loses case against PSG over lack of support after attack
-
Trump - a year of ruling by executive order
-
Iran refusing to allow independent medical examination of Nobel winner: family
-
Brazil megacity Sao Paulo struck by fresh water crisis
-
Australia's Green becomes most expensive overseas buy in IPL history
-
VW stops production at German site for first time
-
Man City star Doku sidelined until new year
-
Rome's new Colosseum station reveals ancient treasures
-
EU eases 2035 combustion-engine ban to boost car industry
-
'Immense' collection of dinosaur footprints found in Italy
-
US unemployment rises further, hovering at highest since 2021
-
Senators grill Trump officials on US alleged drug boat strikes
-
Filmmaker Rob Reiner's son to be formally charged with parents' murder
-
Shift in battle to tackle teens trapped in Marseille drug 'slavery'
-
Stocks retreat on US jobs, oil drops on Ukraine hopes
-
Manchester United 'wanted me to leave', claims Fernandes
-
Serbian President blames 'witch hunt' for ditched Kushner hotel plan
-
Man who hit Liverpool parade jailed for over 21 years
-
Sahel juntas would have welcomed a coup in Benin: analysts
-
PSG ordered to pay around 60mn euros to Mbappe in wage dispute
-
BBC says will fight Trump's $10 bn defamation lawsuit
-
Stocks retreat ahead of US jobs, oil drops on Ukraine hopes
-
Suicide bomber kills five soldiers in northeast Nigeria: sources
-
EU set to drop 2035 combustion-engine ban to boost car industry
-
Australia's Green sold for record 252 mn rupees in IPL auction
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps.
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.
"The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."
NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.
More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.com
About ZeptoMetrix®
ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.
Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355
Contact Information
Andrew Zenger
Global Product Manager
[email protected]
(716) 715-7417
SOURCE: ZeptoMetrix
View the original press release on ACCESS Newswire
D.Schneider--BTB